Table 3.
Association between miRNA biomarker expression and CRC prognosis and metastasis prediction in the CRC tissue cohort (175 FFPE pCRC tissues)*
| Characteristics | Univariate | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Association between miRNA expression and CRC prognosis (Cox proportional hazards model on overall survival) | ||||
| Tumor suppressor–miRNAs | ||||
| Age (>68 y vs ≤68 y) | 0.80 (0.44 to 1.48) | .4816 | 1.53 (0.77 to 3.05) | .2302 |
| Sex (male vs female) | 1.15 (0.61 to 2.16) | .662 | 1.79 (0.88 to 3.64) | .1112 |
| T stage (T3/4 vs T1/2) | 7.94 (1.93 to 32.62) | .0001 | 1.71 (0.39 to 7.48) | .4763 |
| N stage (N1/2/3 vs N0) | 15.18 (5.42 to 42.50) | <.0001 | 6.44 (2.13 to 19.45) | .001 |
| Liver metastasis (present vs absent) | 12.06 (6.08 to 23.94) | <.0001 | 6.69 (2.95 to 15.17) | <.0001 |
| Pathology (poor diff. vs well/mod diff.) | 1.84 (0.77 to 4.37) | .2005 | 4.11 (1.40 to 12.06) | .105 |
| CEA (>5ng/mL vs ≤5ng/mL) | 5.46 (2.28 to 13.08) | <.0001 | 1.60 (0.62 to 4.09) | .3335 |
| hsa-let-7i (low vs high) | 5.35 (1.30 to 22.02) | .0026 | 5.00 (1.02 to 24.35) | .0479 |
| Oncogenic-miRNAs | ||||
| Age (>68 y vs ≤68 y) | 0.80 (0.44 to 1.48) | .4816 | 1.14 (0.58 to 2.24) | .7082 |
| Sex (male vs female) | 1.15 (0.61 to 2.16) | .662 | 1.45 (0.74 to 2.84) | .2807 |
| T stage (T3/4 vs T1/2) | 7.94 (1.93 to 32.62) | .0001 | 1.96 (0.44 to 8.69) | .3792 |
| N stage (N1/2/3 vs N0) | 15.18 (5.42 to 42.50) | <.0001 | 6.29 (2.04 to 19.38) | .0015 |
| Liver metastasis (present vs absent) | 12.06 (6.08 to 23.94) | <.0001 | 5.95 (2.58 to 13.69) | <.0001 |
| Pathology (poor diff. vs well/mod diff.) | 1.84 (0.77 to 4.37) | .2005 | 2.47 (0.90 to 6.77) | .0794 |
| CEA (>5ng/mL vs ≤5ng/mL) | 5.46 (2.28 to 13.08) | <.0001 | 1.67 (0.63 to 4.45) | .3039 |
| hsa-miR-10b (high vs low) | 1.57 (0.66 to 3.70) | .3097 | 0.82 (0.35 to 1.96) | .6623 |
| Association between miRNA expression and CRC distant metastasis (logistic regression model) | ||||
| Tumor suppressor–miRNAs | ||||
| Age (>68 y vs ≤68 y) | 0.56 (0.29 to 1.11) | .0958 | 0.54 (0.22 to 1.32) | .1778 |
| Sex (male vs female) | 1.08 (0.55 to 2.13) | .8166 | 1.21 (0.49 to 2.98) | .682 |
| T stage (T3/4 vs T1/2) | 5.38 (1.83 to 15.83) | .0022 | 2.04 (0.49 to 8.57) | .3294 |
| N stage (N1/2/3 vs N0) | 33.17 (9.78 to 112.48) | <.0001 | 23.37 (6.55 to 83.46) | <.0001 |
| hsa-let-7i (low vs high) | 5.99 (1.37 to 26.19) | .0175 | 5.54 (1.14 to 26.80) | .0334 |
| Oncogenic-miRNAs | ||||
| Age (>68 y vs ≤68 y) | 0.56 (0.29 to 1.11) | .0958 | 0.41 (0.17 to 1.01) | .0533 |
| Sex (male vs female) | 1.08 (0.55 to 2.13) | .8166 | 1.23 (0.49 to 3.06) | .6615 |
| T stage (T3/4 vs T1/2) | 5.38 (1.83 to 15.83) | .0022 | 2.41 (0.57 to 10.13) | .2301 |
| N stage (N1/2/3 vs N0) | 33.17 (9.78 to 112.48) | <.0001 | 25.34 (7.02 to 91.48) | <.0001 |
| hsa-miR-10b (high vs low) | 2.86 (0.82 to 10.02) | .05 | 4.91 (1.22 to 19.73) | .0248 |
* All statistical tests were two-sided. CI = confidence interval; CRC = colorectal cancer; HR = hazard ratio; miRNA = microRNA; N stage = lymph node metastasis in Union for International Cancer Control classification; OR = odds ratio; T stage = tumor depth.